Literature DB >> 17822717

Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats.

SuJean Choi1, Briana DiSilvio, JayLynn Unangst, John D Fernstrom.   

Abstract

Many antipsychotics cause weight gain in humans, but usually not in rats, when injected once or twice daily. Since blood antipsychotic half-lives are short in rats, compared to humans, chronic administration by constant infusion may be necessary to see consistent weight gain in rats. Male and female rats were implanted with mini-pumps for constant infusion of olanzapine (5 mg/kg/day), clozapine (10 mg/kg/day) or vehicle for 11 days. Food intake and body weight were measured; blood drug levels were measured by HPLC. Olanzapine increased food intake and body weight in female, but not male rats. Serum olanzapine concentrations were 30-35 ng/ml. Clozapine had no effect on food intake or body weight in female or male rats. Serum clozapine concentrations were about 75 ng/ml. Single-dose pharmacokinetic analysis revealed a serum terminal half-life of 1.2-1.5 h for each drug, with no sex differences. Despite the fact that olanzapine and clozapine promote weight gain in humans, these drugs appear to have minimal effects on body weight and food intake in rats, except for a modest effect of olanzapine in female rats, even though therapeutic levels of olanzapine are achieved in serum during chronic infusion. Hence, the rapid clearance of drug following single administration in previous studies cannot explain the weak or absent effects of antipsychotics on weight gain in this species. The rat thus appears to be an inadequate model of weight gain produced by some antipsychotics in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17822717      PMCID: PMC3998666          DOI: 10.1016/j.lfs.2007.08.009

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  29 in total

Review 1.  Antipsychotic-induced weight gain: a review of the literature.

Authors:  D B Allison; D E Casey
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

2.  Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

Authors:  B R Basson; B J Kinon; C C Taylor; K A Szymanski; J A Gilmore; G D Tollefson
Journal:  J Clin Psychiatry       Date:  2001-04       Impact factor: 4.384

Review 3.  Serum clozapine levels: a review of their clinical utility.

Authors:  Catherine Greenwood-Smith; Dan I Lubman; David J Castle
Journal:  J Psychopharmacol       Date:  2003-06       Impact factor: 4.153

4.  Weight gain associated with antipsychotic drugs.

Authors:  R Ganguli
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

5.  Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities.

Authors:  G D Cooper; L C Pickavance; J P H Wilding; J A Harrold; J C G Halford; A J Goudie
Journal:  J Psychopharmacol       Date:  2006-10-18       Impact factor: 4.153

6.  Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial.

Authors:  P J Perry; B C Lund; T Sanger; C Beasley
Journal:  J Clin Psychopharmacol       Date:  2001-02       Impact factor: 3.153

Review 7.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 8.  What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.

Authors:  Peter Schulte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.

Authors:  B Pouzet; T Mow; M Kreilgaard; S Velschow
Journal:  Pharmacol Biochem Behav       Date:  2003-04       Impact factor: 3.533

10.  Characterization of olanzapine-induced weight gain in rats.

Authors:  Andrew J Goudie; Judith A Smith; Jason C G Halford
Journal:  J Psychopharmacol       Date:  2002-12       Impact factor: 4.153

View more
  23 in total

1.  Meal-induced insulin sensitization is preserved after acute olanzapine administration in female Sprague-Dawley rats.

Authors:  Diána Kovács; Csaba Hegedűs; Rita Kiss; Réka Sári; József Németh; Zoltán Szilvássy; Barna Peitl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-03       Impact factor: 3.000

2.  Effects of early postnatal sibling deprivation on anxiety and vulnerability to cocaine in offspring rats.

Authors:  Yan-Qin Li; Xiao-Yi Wang; Hai-Feng Zhai; Yong-Qiu Zheng; Xiang Yang Zhang; Therese Kosten; Lin Lu
Journal:  Psychopharmacology (Berl)       Date:  2008-05-02       Impact factor: 4.530

3.  A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats.

Authors:  Ei Sejima; Atsushi Yamauchi; Tsuyoshi Nishioku; Mitsuhisa Koga; Kengo Nakagama; Shinya Dohgu; Kojiro Futagami; Yasufumi Kataoka
Journal:  Cell Mol Neurobiol       Date:  2011-06-17       Impact factor: 5.046

4.  Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters.

Authors:  Kieran J Davey; Siobhain M O'Mahony; Harriet Schellekens; Orla O'Sullivan; John Bienenstock; Paul D Cotter; Timothy G Dinan; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2012-01-11       Impact factor: 4.530

5.  Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents.

Authors:  Sun H Kim; Lilla Nikolics; Fahim Abbasi; Cindy Lamendola; James Link; Gerald M Reaven; Steven Lindley
Journal:  J Psychiatr Res       Date:  2009-12-03       Impact factor: 4.791

6.  Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine.

Authors:  Nima Davoodi; Mikhail Kalinichev; Sergei A Korneev; Peter G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

Review 7.  Atypical antipsychotics and effects on feeding: from mice to men.

Authors:  Louise Benarroch; Chantel Kowalchuk; Virginia Wilson; Celine Teo; Melanie Guenette; Araba Chintoh; Yasika Nesarajah; Valerie Taylor; Peter Selby; Paul Fletcher; Gary J Remington; Margaret K Hahn
Journal:  Psychopharmacology (Berl)       Date:  2016-06-01       Impact factor: 4.530

8.  Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway.

Authors:  Xue-Mei Liu; Xiao-Min Zhao; Chao Deng; Yan-Ping Zeng; Chang-Hua Hu
Journal:  Acta Pharmacol Sin       Date:  2019-02-06       Impact factor: 6.150

9.  Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways.

Authors:  V Mondelli; C Anacker; A C Vernon; A Cattaneo; S Natesan; M Modo; P Dazzan; S Kapur; C M Pariante
Journal:  Transl Psychiatry       Date:  2013-01-15       Impact factor: 6.222

10.  Beneficial effect of Zingiber officinale on olanzapine-induced weight gain and metabolic changes.

Authors:  Mrityunjaya B Ullagaddi; B M Patil; Pukar Khanal
Journal:  J Diabetes Metab Disord       Date:  2021-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.